

A1 Sub B1 This application claims priority to PCT/AU01/00849, filed on July 13, 2001, and Australian Provisional Patent Application No. PQ 8795, filed July 14, 2000. The entire content of both these applications are incorporated by reference.

In the Claims

Please cancel claims 1-12, without prejudice or disclaimer.

Please add the following claims:

- A2*
13. (New) A method of preventing metastasis of a cellular proliferative disease comprising the step of administering to a subject in need thereof a therapeutically effective amount of hyaluronan
 14. (New) The method of claim 13, wherein said hyaluron is provided in combination with one or more of a pharmaceutical carrier, adjuvant or vehicle.
 15. (New) The method according to claim 13, wherein the cellular proliferative disorder is selected from the group consisting of cancers of the breast, lung, prostate, kidney, skin, neural, ovary, uterus, liver, pancreas, epithelial, gastric, intestinal, exocrine, endocrine, lymphatic, hematopoietic system or head and neck tissue.
 16. (New) The method according to claim 13, wherein the subject is a mammal.
 17. (New) The method according to claim 16, wherein the mammal is selected from the group consisting of bovine, canine, equine, feline, porcine and human.

18. (New) The method according to claim 13, further comprising the step of administering a chemotherapeutic agent.
19. (New) The method of claim 18, wherein the bioavailability of the chemotherapeutic agent is enhanced.
20. (New) The method according to claim 18, wherein the administration of hyaluronan is prior to or subsequent to the administration of the chemotherapeutic agent.
21. (New) The method according to claim 18, wherein the chemotherapeutic agent is selected from the group consisting of carmustine (BCNU), chlorambucil (Leukeran), cisplatin (Platinol), Cytarabine, doxorubicin (Adriamycin), fluorouracil (5-FU), methotrexate (mexate), CPT111, etoposide, pliamycin (Mithracin) and taxanes.
22. (New) The method according to claim 21, wherein the chemotherapeutic agent is fluorouracil (5-FU).
23. (New) The method according to claim 13, wherein the administration is orally, topically, or parenterally.
24. (New) The method according to claim 23, wherein parenteral administration is by subcutaneous injection, aerosol, intravenous, intramuscular, intrathecal, intracranial, intrasternal injection or infusion techniques.
25. (New) A method of treating a cellular proliferative disease comprising the step of administering to a subject in need thereof a therapeutically effective amount of a composition comprising hyaluronan and a chemotherapeutic agent.

26. (New) The method of claim 25, wherein said hyaluron is provided in combination with one or more of a pharmaceutical carrier, adjuvant or vehicle.
27. (New) The method according to claim 25, wherein the cellular proliferative disorder is selected from the group consisting of cancers of the breast, lung, prostate, kidney, skin, neural, ovary, uterus, liver, pancreas, epithelial, gastric, intestinal, exocrine, endocrine, lymphatic, hematopoietic system or head and neck tissue.
28. (New) The method according to claim 25, wherein the subject is a mammal.
29. (New) The method according to claim 28, wherein the mammal is selected from the group consisting of bovine, canine, equine, feline, porcine and human.
30. (New) The method according to claim 25, wherein the bioavailability of the chemotherapeutic agent is enhanced.
31. (New) The method according to claim 25, wherein the administration of hyaluronan is prior to or subsequent to the administration of the chemotherapeutic agent.
32. (New) The method according to claim 25, wherein the chemotherapeutic agent is selected from the group consisting of carmustine (BCNU), chlorambucil (Leukeran), cisplatin (Platinol), Cytarabine, doxorubicin (Adriamycin), fluorouracil (5-FU), methotrexate (mexate), CPT111, etoposide, pliamycin (Mithracin) and taxanes.
33. (New) The method according to claim 32, wherein the chemotherapeutic agent is fluorouracil (5-FU).

34. (New) The method according to claim 25, wherein the administration is orally, topically, or parenterally.
35. (New) The method according to claim 34, wherein parenteral administration is by subcutaneous injection, aerosol, intravenous, intramuscular, intrathecal, intracranial, intrasternal injection or infusion techniques.
36. (New) A method of treating a drug resistant disease in a subject in need thereof comprising the step of administering to said subject a therapeutically effective amount of hyaluronan in conjunction with a chemotherapeutic agent.
- AP 37. (New) The method of claim 36, wherein said hyaluron is provided in combination with one or more of a pharmaceutical carrier, adjuvant or vehicle.
38. (New) The method according to claim 36, wherein the drug resistant disease is a cellular proliferative disorder.
39. (New) The method according to claim 36, wherein the cellular proliferative disorder is selected from the group consisting of cancers of the breast, lung, prostate, kidney, skin, neural, ovary, uterus, liver, pancreas, epithelial, gastric, intestinal, exocrine, endocrine, lymphatic, hematopoietic system or head and neck tissue.
40. (New) The method according to claim 36, wherein the subject is a mammal.
41. (New) The method according to claim 40, wherein the mammal is selected from the group consisting of bovine, canine, equine, feline, porcine and human.
42. (New) The method according to claim 36, wherein the administration of hyaluronan is prior to or subsequent to the administration of the chemotherapeutic agent.

- A2
43. (New) The method according to claim 36, wherein the bioavailability of the chemotherapeutic agent is enhanced.
 44. (New) The method according to claim 36, wherein the chemotherapeutic agent is selected from the group consisting of carmustine (BCNU), chlorambucil (Leukeran), cisplatin (Platinol), Cytarabine, doxorubicin (Adriamycin), fluorouracil (5-FU), methotrexate (mexate), CPT111, etoposide, pliamycin (Mithracin) and taxanes.
 45. (New) The method according to claim 44, wherein the chemotherapeutic agent is fluorouracil (5-FU).
 46. (New) The method according to claim 36, wherein the administration is orally, topically, or parenterally.
 47. (New) The method according to claim 46, wherein parenteral administration is either by subcutaneous injection, aerosol, intravenous, intramuscular, intrathecal, intracranial, intrasternal injection or infusion techniques.
 48. (New) A composition comprising a therapeutically effective amount of hyaluronan in combination with a pharmaceutical carrier, adjuvant or vehicle.
 49. (New) The composition according to claim 48, further comprising a chemotherapeutic agent.
 50. (New) The composition according to claim 49, wherein the chemotherapeutic agent is selected from the group consisting of carmustine (BCNU), chlorambucil (Leukeran), cisplatin (Platinol), Cytarabine, doxorubicin (Adriamycin), fluorouracil (5-FU), methotrexate (mexate), CPT111, etoposide, pliamycin (Mithracin) and taxanes.
-